Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (NASDAQ: AKTX) has announced promising preclinical data for its novel ADC spliceosome modulating payload, PH1, targeting hormone refractory prostate cancer. The data demonstrates PH1's ability to suppress AR-V7 receptor levels, which drives metastatic castration resistant prostate cancer (mCRPC) progression.
The research showed PH1's effectiveness in both hormone-refractory and hormone-sensitive prostate cancer models. In hormone-sensitive cases, PH1 showed additive effects when combined with existing treatments like Xtandi and Erleada. This suggests potential for developing first-line combination therapies and addressing the significant unmet need in ARPI-resistant cases, where current treatment options are limited.
Akari Therapeutics (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its novel antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment. The patent covers the platform's unique mechanism of modulating alternative splicing within cancer cells.
The technology targets cancer cells' ability to hijack alternative splicing (AS) processes, which affects tumor formation, growth, and metastasis. The PH1 payload demonstrates potential in disrupting cancer cell survival mechanisms across multiple types of cancers, including those resistant to current therapies.
The patent strengthens Akari's intellectual property portfolio and supports the development of their ADC programs, including AKTX-101 (Trop2 ADC with PH1 payload) and AKTX-102 (undisclosed target).
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event.
The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor "What This Means" segment featuring CEO Abizer Gaslightwala. The presentation focuses on the company's novel spliceosome modulator payload, PH1, which is being developed as part of their antibody drug conjugates (ADCs) platform for cancer treatment.
During the segment, Gaslightwala discussed ongoing research efforts to understand how the PH1 payload can disrupt key drivers of cancer cell growth, highlighting the company's commitment to advancing their oncology pipeline.
Akari Therapeutics (NASDAQ:AKTX) is advancing research on its novel antibody drug conjugate (ADC) payload PH1, a spliceosome modulator designed for cancer treatment. The company highlighted that PH1 demonstrates multiple mechanisms of action, including cancer cell death induction and immune system activation against tumors.
Key features of PH1 include its ability to target cancers driven by oncogenic factors like KRAS, BRAF, and FGFR3, reduced off-target toxicity through engineered linker technology, and resistance to standard efflux transporters. The company expects to release new preclinical data on PH1's impact against a key oncogenic driver before the end of 2025.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.
The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.